متابعة
Peter Caravan
Peter Caravan
Martinos Center for Biomedical Imaging, Institute for Innovation in Imaging (i3), MGH, Harvard
بريد إلكتروني تم التحقق منه على mgh.harvard.edu
عنوان
عدد مرات الاقتباسات
عدد مرات الاقتباسات
السنة
Gadolinium (III) chelates as MRI contrast agents: structure, dynamics, and applications
P Caravan, JJ Ellison, TJ McMurry, RB Lauffer
Chem. Rev 99, 2293-2352, 1999
56401999
Strategies for increasing the sensitivity of gadolinium based MRI contrast agents
P Caravan
Chemical Society Reviews 35 (6), 512-523, 2006
17542006
The chemistry of contrast agents in medical magnetic resonance imaging
AS Merbach, L Helm, É Tóth
John Wiley & Sons, 2013
17502013
Chemistry of MRI contrast agents: current challenges and new frontiers
J Wahsner, EM Gale, A Rodríguez-Rodríguez, P Caravan
Chemical reviews 119 (2), 957-1057, 2018
14622018
Biodistribution of gadolinium‐based contrast agents, including gadolinium deposition
S Aime, P Caravan
Journal of Magnetic Resonance Imaging: An Official Journal of the …, 2009
6552009
Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium‐ and manganese‐based T1 contrast agents
P Caravan, CT Farrar, L Frullano, R Uppal
Contrast media & molecular imaging 4 (2), 89-100, 2009
6352009
The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates
P Caravan, NJ Cloutier, MT Greenfield, SA McDermid, SU Dunham, ...
Journal of the American Chemical Society 124 (12), 3152-3162, 2002
5622002
Primer on gadolinium chemistry
AD Sherry, P Caravan, RE Lenkinski
Journal of magnetic resonance imaging: an official journal of the …, 2009
5142009
Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action
P Caravan
Accounts of chemical research 42 (7), 851-862, 2009
4592009
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma
BC Fuchs, Y Hoshida, T Fujii, L Wei, S Yamada, GY Lauwers, CM McGinn, ...
Hepatology 59 (4), 1577-1590, 2014
3642014
A manganese alternative to gadolinium for MRI contrast
EM Gale, IP Atanasova, F Blasi, I Ay, P Caravan
Journal of the American Chemical Society 137 (49), 15548-15557, 2015
3562015
Reaction chemistry of BMOV, bis (maltolato) oxovanadium (IV), a potent insulin mimetic agent
C Orvig, P Caravan, L Gelmini, N Glover, FG Herring, H Li, JH McNeill, ...
Journal of the American Chemical Society 117 (51), 12759-12770, 1995
3471995
Collagen-targeted MRI contrast agent for molecular imaging of fibrosis
P Caravan, B Das, S Dumas, FH Epstein, PA Helm, V Jacques, S Koerner, ...
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION IN ENGLISH- 46 (43), 8171, 2007
2972007
EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus
K Overoye-Chan, S Koerner, RJ Looby, AF Kolodziej, SG Zech, Q Deng, ...
Journal of the American Chemical Society 130 (18), 6025-6039, 2008
2612008
Gut microbiota is critical for the induction of chemotherapy-induced pain
S Shen, G Lim, Z You, W Ding, P Huang, C Ran, J Doheny, P Caravan, ...
Nature neuroscience 20 (9), 1213-1216, 2017
2592017
Clinical magnetic resonance imaging
RR Edelman, JR Hesselink
(No Title), 2006
2162006
Contrast agents for MRI: 30+ years and where are we going?
VC Pierre, MJ Allen, P Caravan
JBIC Journal of Biological Inorganic Chemistry 19, 127-131, 2014
2152014
Bimodal MR-PET agent for quantitative pH imaging
L Frullano, C Catana, T Benner, AD Sherry, P Caravan
Angewandte Chemie (International ed. in English) 49 (13), 2382, 2010
2012010
Postinfarction Myocardial Scarring in Mice: Molecular MR Imaging with Use of a Collagen-targeting Contrast Agent1
PA Helm, P Caravan, BA French, V Jacques, L Shen, Y Xu, RJ Beyers, ...
Radiology 247 (3), 788-796, 2008
1972008
Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility
J Vymazal, E Spuentrup, G Cardenas-Molina, AJ Wiethoff, MG Hartmann, ...
Investigative radiology 44 (11), 697-704, 2009
1922009
يتعذر على النظام إجراء العملية في الوقت الحالي. عاود المحاولة لاحقًا.
مقالات 1–20